Maria Patrizia Carrieri1,2, Camelia Protopopescu3,4, Zobair Younossi5, Antoine Vilotitch1,2, Hélène Fontaine6,7, Ventzislava Petrov-Sanchez8, Fabienne Marcellin1,2, Fabrice Carrat9,10, Christophe Hézode11, Marc Bourlière12. 1. Faculté de Médecine, Aix Marseille University, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, 27 Bd. Jean Moulin, 13385, Marseille Cedex 5, France. 2. ORS PACA (Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur), Marseille, France. 3. Faculté de Médecine, Aix Marseille University, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, 27 Bd. Jean Moulin, 13385, Marseille Cedex 5, France. camelia.protopopescu@inserm.fr. 4. ORS PACA (Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur), Marseille, France. camelia.protopopescu@inserm.fr. 5. Department of Medicine, Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, Annandale, VA, 22039, USA. 6. INSERM, U1016, Hôpital Cochin, 27 rue du Faubourg Saint Jacques, 75014, Paris, France. 7. Hepatology Unit, Groupe hospitalier Cochin-Hôtel Dieu, AP-HP, Paris, France. 8. Unit for Basic and Clinical Research on Viral Hepatitis, ANRS (France Recherche Nord and Sud Sida-HIV Hépatites FRENSH), Paris, France. 9. Sorbonne Universities, UPMC University of Paris 06, INSERM, Pierre Louis Institute of Epidemiology and Public Health (IPLESP UMRS 1136), Paris, France. 10. Public Health Unit, Hôpital Saint-Antoine, AP-HP, Paris, France. 11. Department of Hepatology and Gastroenterology, Hôpital Henri Mondor, AP-HP, University of Paris-Est, INSERM, U955, Créteil, France. 12. Department of Hepato-Gastroenterology, Hôpital Saint Joseph, Marseille, France.
Abstract
OBJECTIVE: We aimed to compare health-related quality of life (HRQL) during and after hepatitis C virus (HCV) treatment in patients receiving pegylated-interferon (PEG-IFN)-containing therapy (including boceprevir or telaprevir-ANRS CO20 CUPIC cohort) who subsequently switched to PEG-IFN-free regimens (sofosbuvir + ledipasvir with or without ribavirin [RBV]-SIRIUS trial). METHODS: Two analyses were performed. The first compared physical (PCS) and mental (MCS) HRQL (MOS SF-12) scores during treatment between CUPIC and SIRIUS. The second compared PCS and MCS scores after treatment end between CUPIC and SIRIUS. The analyses used linear regression mixed models adjusted for pre-treatment HRQL scores, gender, and age at each visit. RESULTS: Among patients enrolled successively in both studies, 43 (corresponding to 212 HRQL assessments) and 43 (82 HRQL assessments) were eligible for the 'during' and 'post' treatment analyses, respectively. In the 'during-treatment' analysis, we found significantly higher PCS and MCS values during PEG-IFN-free treatment than for PEG-IFN-containing treatment. In the 'post-treatment' analysis, results showed significantly higher MCS values after PEG-IFN-free treatment than after PEG-IFN-containing treatment. No significant difference was found for PCS in the post-treatment analysis. CONCLUSIONS: These results highlight an improvement in both physical and mental HRQL during HCV treatment, but no major improvement in physical HRQL after treatment end, when comparing PEG-IFN-free regimens with PEG-IFN-containing regimens. This suggests that in the PEG-IFN-free regimens era, screening and comprehensive care of comorbidities and residual somatic symptoms during treatment, and especially after HCV clearance, are still needed to improve patient outcomes.
OBJECTIVE: We aimed to compare health-related quality of life (HRQL) during and after hepatitis C virus (HCV) treatment in patients receiving pegylated-interferon (PEG-IFN)-containing therapy (including boceprevir or telaprevir-ANRS CO20 CUPIC cohort) who subsequently switched to PEG-IFN-free regimens (sofosbuvir + ledipasvir with or without ribavirin [RBV]-SIRIUS trial). METHODS: Two analyses were performed. The first compared physical (PCS) and mental (MCS) HRQL (MOS SF-12) scores during treatment between CUPIC and SIRIUS. The second compared PCS and MCS scores after treatment end between CUPIC and SIRIUS. The analyses used linear regression mixed models adjusted for pre-treatment HRQL scores, gender, and age at each visit. RESULTS: Among patients enrolled successively in both studies, 43 (corresponding to 212 HRQL assessments) and 43 (82 HRQL assessments) were eligible for the 'during' and 'post' treatment analyses, respectively. In the 'during-treatment' analysis, we found significantly higher PCS and MCS values during PEG-IFN-free treatment than for PEG-IFN-containing treatment. In the 'post-treatment' analysis, results showed significantly higher MCS values after PEG-IFN-free treatment than after PEG-IFN-containing treatment. No significant difference was found for PCS in the post-treatment analysis. CONCLUSIONS: These results highlight an improvement in both physical and mental HRQL during HCV treatment, but no major improvement in physical HRQL after treatment end, when comparing PEG-IFN-free regimens with PEG-IFN-containing regimens. This suggests that in the PEG-IFN-free regimens era, screening and comprehensive care of comorbidities and residual somatic symptoms during treatment, and especially after HCV clearance, are still needed to improve patient outcomes.
Authors: Brennan M R Spiegel; Zobair M Younossi; Ron D Hays; Dennis Revicki; Sean Robbins; Fasiha Kanwal Journal: Hepatology Date: 2005-04 Impact factor: 17.425
Authors: Marc Bourlière; Jean-Pierre Bronowicki; Victor de Ledinghen; Christophe Hézode; Fabien Zoulim; Philippe Mathurin; Albert Tran; Dominique G Larrey; Vlad Ratziu; Laurent Alric; Robert H Hyland; Deyuan Jiang; Brian Doehle; Phillip S Pang; William T Symonds; G Mani Subramanian; John G McHutchison; Patrick Marcellin; François Habersetzer; Dominique Guyader; Jean-Didier Grangé; Véronique Loustaud-Ratti; Lawrence Serfaty; Sophie Metivier; Vincent Leroy; Armand Abergel; Stanislas Pol Journal: Lancet Infect Dis Date: 2015-03-13 Impact factor: 25.071
Authors: Michael J Zoratti; Ayesha Siddiqua; Rita E Morassut; Dena Zeraatkar; Roger Chou; Judith van Holten; Feng Xie; Eric Druyts Journal: EClinicalMedicine Date: 2020-01-05
Authors: R Ragusa; G Bertino; A Bruno; E Frazzetto; F Cicciu; G Giorgianni; L Lupo Journal: Health Qual Life Outcomes Date: 2018-01-17 Impact factor: 3.186